Recent News

• 05.29.2025 - Ashland Innovation Day 2025
• 05.01.2025 - 2nd Quarter 2025 Earnings Call
• 04.17.2025 - Ashland sets date for second-quarter fiscal 2025 earnings release and conference call webcast
• 04.03.2025 - Ashland unveils collapeptyl™, a revolutionary biofunctional delivering superior performance for the collaverse™ ecosystem
• 04.01.2025 - Ashland innovative platform technologies and personal care ingredients demonstrate meaningful growth opportunities for customers at in-cosmetics Global, Amsterdam
• 04.01.2025 - Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest
• 03.28.2025 - Ashland to host 2025 Innovation Day for analysts and investors
• 03.24.2025 - Ashland showcases innovative, environmentally sustainable¹ additives for coatings and specialty markets at European Coatings Show
• 03.17.2025 - Ashland completes sale of Avoca business to Mane
• 03.03.2025 - Ashland increases prices for 1-4 Butanediol intermediates and solvents product range globally

Recent Filings

• 04.17.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.29.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]